Pub Date : 2025-10-01DOI: 10.1016/j.nefro.2025.501333
Maryam Adnan , Hamza Naveed , Mohammad Hamza , Burhan Khalid , Wasif Safdar , Jawad Basit , Sameh Nassar , Prakash Upreti , Maha Zafar , Zainab Javeed , Marloe Prince , Yasar Sattar , M. Chadi Alraies
Background
Resistant hypertension presents a clinical challenge. The efficacy of renal denervation (RDN) as a potential treatment has conflicting data. Multiple randomized controlled trials have been conducted to assess the impact of RDN.
Methods
We performed systematic search of the PubMed and EMBASE from inception to April 2024 to identify studies comparing various interventions for resistant hypertension. We employed a frequentist network meta-analysis model, utilizing the net-meta module and applying a random effects model in CRAN-R software.
Results
Data of 2553 patients from 20 RCTs was analyzed. Standard mean differences (SMDs) for diastolic blood pressure (DBP) and systolic blood pressure (SBP) were assessed at different time points, including daytime, nighttime, over 24 h, and during office visits. Our results demonstrate an improvement in various BP parameters when comparing RDN with sham: daytime DBP (3.46, 95%CI: [1.89–5.02], P < 0.0001), nighttime SBP (2.87, 95%CI: [1.43–4.31], P < 0.0001), 24-h SBP (2.82, 95%CI: [1.24–4.41], P = 0.001), and in-office DBP (2.70, 95%CI: [1.04–4.36], P = 0.002). However, no statistically significant difference was found in daytime SBP (3.60, 95% CI: [−0.67–7.87], P = 0.10), nighttime DBP (1.65, 95% CI: [−0.57–3.86], P = 0.15) and in-office SBP (3.89, 95% CI: [−10.07–17.86], P = 0.60) and in 24-h DBP.
Conclusion
Our study supports the efficacy of RDN, when combined with antihypertensive treatment when compared to sham treatment, in the management of resistant hypertension.
背景：顽固性高血压是一项临床挑战。肾去神经支配（RDN）作为一种潜在的治疗方法的有效性存在矛盾的数据。已经进行了多个随机对照试验来评估RDN的影响。方法系统检索PubMed和EMBASE从成立到2024年4月，以确定比较各种干预措施治疗顽固性高血压的研究。我们采用频率网络元分析模型，利用net-meta模块，并在CRAN-R软件中应用随机效应模型。结果分析了20项随机对照试验2553例患者的资料。舒张压（DBP）和收缩压（SBP）的标准平均差值（SMDs）在不同的时间点进行评估，包括白天、夜间、24小时内和办公室就诊期间。我们的研究结果表明，与假手术相比，RDN改善了各种血压参数：白天舒张压（3.46,95%CI: [1.89-5.02], P < 0.0001），夜间舒张压（2.87,95%CI: [1.43-4.31], P < 0.0001）， 24小时舒张压（2.82,95%CI: [1.24-4.41], P = 0.001），办公室舒张压（2.70,95%CI: [1.04-4.36], P = 0.002）。然而，白天收缩压（3.60,95% CI:[−0.67-7.87],P = 0.10）、夜间舒张压（1.65,95% CI:[−0.57-3.86],P = 0.15）、办公室舒张压（3.89,95% CI:[−10.07-17.86],P = 0.60）和24小时舒张压无统计学差异。结论本研究支持RDN联合降压治疗在治疗顽固性高血压方面的疗效。
{"title":"Efficacy of renal denervation with and without antihypertensives in patients with resistant hypertension: A systematic review and meta-analysis","authors":"Maryam Adnan , Hamza Naveed , Mohammad Hamza , Burhan Khalid , Wasif Safdar , Jawad Basit , Sameh Nassar , Prakash Upreti , Maha Zafar , Zainab Javeed , Marloe Prince , Yasar Sattar , M. Chadi Alraies","doi":"10.1016/j.nefro.2025.501333","DOIUrl":"10.1016/j.nefro.2025.501333","url":null,"abstract":"<div><h3>Background</h3><div>Resistant hypertension presents a clinical challenge. The efficacy of renal denervation (RDN) as a potential treatment has conflicting data. Multiple randomized controlled trials have been conducted to assess the impact of RDN.</div></div><div><h3>Methods</h3><div>We performed systematic search of the PubMed and EMBASE from inception to April 2024 to identify studies comparing various interventions for resistant hypertension. We employed a frequentist network meta-analysis model, utilizing the <em>net</em>-<em>meta</em> module and applying a random effects model in CRAN-R software.</div></div><div><h3>Results</h3><div>Data of 2553 patients from 20 RCTs was analyzed. Standard mean differences (SMDs) for diastolic blood pressure (DBP) and systolic blood pressure (SBP) were assessed at different time points, including daytime, nighttime, over 24<!--> <!-->h, and during office visits. Our results demonstrate an improvement in various BP parameters when comparing RDN with sham: daytime DBP (3.46, 95%CI: [1.89–5.02], <em>P</em> <!--><<!--> <!-->0.0001), nighttime SBP (2.87, 95%CI: [1.43–4.31], <em>P</em> <!--><<!--> <!-->0.0001), 24-h SBP (2.82, 95%CI: [1.24–4.41], <em>P</em> <!-->=<!--> <!-->0.001), and in-office DBP (2.70, 95%CI: [1.04–4.36], <em>P</em> <!-->=<!--> <!-->0.002). However, no statistically significant difference was found in daytime SBP (3.60, 95% CI: [−0.67–7.87], <em>P</em> <!-->=<!--> <!-->0.10), nighttime DBP (1.65, 95% CI: [−0.57–3.86], <em>P</em> <!-->=<!--> <!-->0.15) and in-office SBP (3.89, 95% CI: [−10.07–17.86], <em>P</em> <!-->=<!--> <!-->0.60) and in 24-h DBP.</div></div><div><h3>Conclusion</h3><div>Our study supports the efficacy of RDN, when combined with antihypertensive treatment when compared to sham treatment, in the management of resistant hypertension.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"45 8","pages":"Article 501333"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145183731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.nefro.2025.501340
Rafael Santamaria , Carlos Escobar , Unai Aranda , Beatriz Palacios , Margarita Capel , Ignacio Hernández , Ana Cebrián , Roberto Alcázar , Manuel Gorostidi
Objective
Real-world analysis of the clinical profile, treatments, major adverse cardiovascular and renal events (MACE and MARE) in patients with different stages of chronic kidney disease (CKD) as defined by KDIGO guidelines.
Methods
This was an observational, retrospective study using the BIG-PAC database. Adults with ≥1 measurement of estimated glomerular filtration rate (eGFR) and albumin-to-creatinine ratio (UACR) closest to 1st January 2018 (up to 6 months) were included. Patients were followed for two years.
Results
Among 70,385 subjects, 21,127 (30.0%) had CKD based on impaired renal function or increased albuminuria. Age and prevalence of diabetes and cardiovascular disease increased as kidney function decreased, or albuminuria rose. Renin–angiotensin system inhibitors were prescribed in 47.1–76.4% patients classified as G3a–G5 and mildly increased albuminuria (A1), 63.2–79.6% in G1–G5 and moderately increased albuminuria (A2), and 51.2–85.9% in G1–G5 and severely increased albuminuria (A3). The prescription of sodium-glucose cotransporter-2 inhibitors was marginal across KDIGO categories. The incidence rates (per 1000 patient-year) of MACE ranged 102.9–245.2 in patients classified as G3a–G5 A1, 40.7–261.1 in G1–G5 A2, and 69.1–362.3 in G1–G5 A3. Incidence rates of MARE ranged 14.9–454.4 in G3a–G5 A1, 29.8–588.5 in G1–5 A2, and 11.8–637.2 in G1–5 A3.
Conclusions
In real-world, the risk of cardiovascular and renal complications rises as kidney function declines and albuminuria worsens. Guideline-recommended therapies remain underused.
{"title":"Cardiovascular and renal outcomes according to KDIGO stages of chronic kidney disease in the Spanish population: Insights from real-world evidence","authors":"Rafael Santamaria , Carlos Escobar , Unai Aranda , Beatriz Palacios , Margarita Capel , Ignacio Hernández , Ana Cebrián , Roberto Alcázar , Manuel Gorostidi","doi":"10.1016/j.nefro.2025.501340","DOIUrl":"10.1016/j.nefro.2025.501340","url":null,"abstract":"<div><h3>Objective</h3><div>Real-world analysis of the clinical profile, treatments, major adverse cardiovascular and renal events (MACE and MARE) in patients with different stages of chronic kidney disease (CKD) as defined by KDIGO guidelines.</div></div><div><h3>Methods</h3><div>This was an observational, retrospective study using the BIG-PAC database. Adults with ≥1 measurement of estimated glomerular filtration rate (eGFR) and albumin-to-creatinine ratio (UACR) closest to 1st January 2018 (up to 6 months) were included. Patients were followed for two years.</div></div><div><h3>Results</h3><div>Among 70,385 subjects, 21,127 (30.0%) had CKD based on impaired renal function or increased albuminuria. Age and prevalence of diabetes and cardiovascular disease increased as kidney function decreased, or albuminuria rose. Renin–angiotensin system inhibitors were prescribed in 47.1–76.4% patients classified as G3a–G5 and mildly increased albuminuria (A1), 63.2–79.6% in G1–G5 and moderately increased albuminuria (A2), and 51.2–85.9% in G1–G5 and severely increased albuminuria (A3). The prescription of sodium-glucose cotransporter-2 inhibitors was marginal across KDIGO categories. The incidence rates (per 1000 patient-year) of MACE ranged 102.9–245.2 in patients classified as G3a–G5 A1, 40.7–261.1 in G1–G5 A2, and 69.1–362.3 in G1–G5 A3. Incidence rates of MARE ranged 14.9–454.4 in G3a–G5 A1, 29.8–588.5 in G1–5 A2, and 11.8–637.2 in G1–5 A3.</div></div><div><h3>Conclusions</h3><div>In real-world, the risk of cardiovascular and renal complications rises as kidney function declines and albuminuria worsens. Guideline-recommended therapies remain underused.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"45 8","pages":"Article 501340"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145183732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.nefro.2025.501350
Eliecer Soriano Payá , Ismael Arco Adamuz , Ana María García Girón , Francisco José Bermúdez-Jiménez , Elisa Berta Pereira Pérez , Laura Jordán Martínez , María Carmen Olvera-Porcel , Leticia García Mochón , Silvia López Fernández , María José Espigares Huete
Background and objective
Cardiorenal syndrome (CRS) reflects a bidirectional interaction between heart failure (HF) and chronic kidney disease (CKD), with high associated healthcare costs. Hospitalizations due to cardiovascular (CV) events, particularly for decompensated HF, represent most CKD-related costs. Cardiorenal units (CRU) emerge as an innovative strategy to address this complexity through a multidisciplinary approach. This study analyzes the effectiveness and efficiency of CRUs.
Material and methods
Observational, longitudinal, ambispective, and single-center study using an adapted interrupted time-series design. Patients with advanced CKD (eGFR < 30 mL/min/1.73 m2) and HF with reduced left ventricular ejection fraction (LVEF) were included. Clinical, demographic, and care-related data were analyzed during the year before and the year after enrolment. Economic costs were derived from healthcare resource consumption associated with hospital care activities.
Results
In 55 patients (mean age 73.9 ± 8.6 years; 78% male), a 65% reduction in emergency department visits (P = .0001) and a 60.5% reduction in hospitalizations (P = .0015) were observed. The economic analysis revealed cost savings of approximately €700,000, with an average reduction of almost €13,000 per patient/year. After inclusion in the CRU, there was an increased prescription of prognostic drugs, with no significant changes in serum potassium concentration (P = .26) and no evidence of renal function deterioration (pre-vs. post-eGFR: 23.36 ± 7.6 mg/dL vs. 22.44 ± 8.5 mg/dL; P = .17). A significant differential impact was observed in all healthcare outcomes, particularly among patients receiving quadruple therapy.
Conclusion
CRUs emerge as effective and efficient models for the management of cardiorenal syndrome. Randomized controlled studies are needed to validate these findings and optimize healthcare policies.
{"title":"Unidad Cardiorrenal en enfermedad cardiorrenal avanzada: impacto clínico y reducción de costes hospitalarios","authors":"Eliecer Soriano Payá , Ismael Arco Adamuz , Ana María García Girón , Francisco José Bermúdez-Jiménez , Elisa Berta Pereira Pérez , Laura Jordán Martínez , María Carmen Olvera-Porcel , Leticia García Mochón , Silvia López Fernández , María José Espigares Huete","doi":"10.1016/j.nefro.2025.501350","DOIUrl":"10.1016/j.nefro.2025.501350","url":null,"abstract":"<div><h3>Background and objective</h3><div>Cardiorenal syndrome (CRS) reflects a bidirectional interaction between heart failure (HF) and chronic kidney disease (CKD), with high associated healthcare costs. Hospitalizations due to cardiovascular (CV) events, particularly for decompensated HF, represent most CKD-related costs. Cardiorenal units (CRU) emerge as an innovative strategy to address this complexity through a multidisciplinary approach. This study analyzes the effectiveness and efficiency of CRUs.</div></div><div><h3>Material and methods</h3><div>Observational, longitudinal, ambispective, and single-center study using an adapted interrupted time-series design. Patients with advanced CKD (eGFR<!--> <!--><<!--> <!-->30<!--> <!-->mL/min/1.73<!--> <!-->m<sup>2</sup>) and HF with reduced left ventricular ejection fraction (LVEF) were included. Clinical, demographic, and care-related data were analyzed during the year before and the year after enrolment. Economic costs were derived from healthcare resource consumption associated with hospital care activities.</div></div><div><h3>Results</h3><div>In 55 patients (mean age 73.9<!--> <!-->±<!--> <!-->8.6<!--> <!-->years; 78% male), a 65% reduction in emergency department visits (<em>P</em> <!-->=<!--> <!-->.0001) and a 60.5% reduction in hospitalizations (<em>P</em> <!-->=<!--> <!-->.0015) were observed. The economic analysis revealed cost savings of approximately €700,000, with an average reduction of almost €13,000 per patient/year. After inclusion in the CRU, there was an increased prescription of prognostic drugs, with no significant changes in serum potassium concentration (<em>P</em> <!-->=<!--> <!-->.26) and no evidence of renal function deterioration (pre-vs. post-eGFR: 23.36<!--> <!-->±<!--> <!-->7.6<!--> <!-->mg/dL vs. 22.44<!--> <!-->±<!--> <!-->8.5<!--> <!-->mg/dL; <em>P</em> <!-->=<!--> <!-->.17). A significant differential impact was observed in all healthcare outcomes, particularly among patients receiving quadruple therapy.</div></div><div><h3>Conclusion</h3><div>CRUs emerge as effective and efficient models for the management of cardiorenal syndrome. Randomized controlled studies are needed to validate these findings and optimize healthcare policies.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"45 8","pages":"Article 501350"},"PeriodicalIF":2.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145183734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-30DOI: 10.1016/j.nefro.2025.501410
María Isabel Troya , Jordi Bover , Anna Cia Hidalgo , Susana Malumbres , Maya Sánchez-Bayá , Elisabet Massó , Verónica Coll-Brito , Paula Anton-Pampols , Iara da Silva , Jordi Soler-Majoral , Elisabeth Marcos , Beatriz Moreiras Abril , Noemí Pérez-León , Marta Morera García , Joan Pau Golf Zaragoza , Xavier Jusmet Miguel , Yolanda Lejardi Estevez , Rosa López-Alarcón , Ignacio Blanco , Cristian Morales Indiano , Jordi Ara
{"title":"Importancia de la codificación tras el diagnóstico de enfermedad renal crónica: del código N18.9 (CIE/ICD-10) al papel de los laboratorios clínicos","authors":"María Isabel Troya , Jordi Bover , Anna Cia Hidalgo , Susana Malumbres , Maya Sánchez-Bayá , Elisabet Massó , Verónica Coll-Brito , Paula Anton-Pampols , Iara da Silva , Jordi Soler-Majoral , Elisabeth Marcos , Beatriz Moreiras Abril , Noemí Pérez-León , Marta Morera García , Joan Pau Golf Zaragoza , Xavier Jusmet Miguel , Yolanda Lejardi Estevez , Rosa López-Alarcón , Ignacio Blanco , Cristian Morales Indiano , Jordi Ara","doi":"10.1016/j.nefro.2025.501410","DOIUrl":"10.1016/j.nefro.2025.501410","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"45 9","pages":"Article 501410"},"PeriodicalIF":2.6,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145384317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-27DOI: 10.1016/j.nefro.2025.501409
María Dolores Arenas Jiménez, Julia Audije-Gil, Paula Manso, David Hernán, Fabiola Dapena, Ana Balseiro, Cristina Sanz
{"title":"Alfabetización en salud renal en la era digital: la experiencia de la plataforma Salud Renal Siempre","authors":"María Dolores Arenas Jiménez, Julia Audije-Gil, Paula Manso, David Hernán, Fabiola Dapena, Ana Balseiro, Cristina Sanz","doi":"10.1016/j.nefro.2025.501409","DOIUrl":"10.1016/j.nefro.2025.501409","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"45 10","pages":"Article 501409"},"PeriodicalIF":2.6,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145610410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Focal segmental glomerulosclerosis (FSGS) is a histopathological lesion characterized by scarring in specific sections of some glomeruli, accompanied by podocyte injury. Worldwide, the prevalence of FSGS and its temporal trends have not been sufficiently studied. However, some reports suggest an increase in the frequency of FSGS in recent decades. Understanding the epidemiology of FSGS is crucial for clinicians to improve diagnosis and treatment.
Objective
This study critically evaluates global prevalence trends of FSGS over the past 32 years (1992–2024), highlighting variations between countries through a systematic review.
Methods
A systematic search of Medline, Embase and ScienceDirect was conducted to identify relevant studies. The reliability of prevalence data was assessed by critical appraisal of selected publications.
Results
The prevalence of FSGS varies significantly between regions. East Asian countries have a relatively low prevalence, with a mean around 7%. In contrast, countries in South Asia, the Middle East and the Americas have a higher prevalence of around 18%. European countries show an intermediate prevalence of about 11%. African countries do not show a clear pattern, with high and low prevalence rates in different countries.
Conclusions
The prevalence of FSGS differs by geographic region and ethnicity. While South Asian countries have maintained a consistently low prevalence, other regions have experienced an increase in FSGS cases over time. This study improves the understanding of global patterns of FSGS, providing valuable epidemiological insights for clinicians and researchers.
{"title":"An approximation to the prevalence of focal segmental glomerulosclerosis: A systematic review of world literature over the past 32 years","authors":"Citlalli Orizaga-de-la-Cruz , Francisco Alejandro Lagunas-Rangel , Anel Gómez-García , Venice Chávez-Valencia","doi":"10.1016/j.nefro.2025.501404","DOIUrl":"10.1016/j.nefro.2025.501404","url":null,"abstract":"<div><h3>Background</h3><div>Focal segmental glomerulosclerosis (FSGS) is a histopathological lesion characterized by scarring in specific sections of some glomeruli, accompanied by podocyte injury. Worldwide, the prevalence of FSGS and its temporal trends have not been sufficiently studied. However, some reports suggest an increase in the frequency of FSGS in recent decades. Understanding the epidemiology of FSGS is crucial for clinicians to improve diagnosis and treatment.</div></div><div><h3>Objective</h3><div>This study critically evaluates global prevalence trends of FSGS over the past 32 years (1992–2024), highlighting variations between countries through a systematic review.</div></div><div><h3>Methods</h3><div>A systematic search of Medline, Embase and ScienceDirect was conducted to identify relevant studies. The reliability of prevalence data was assessed by critical appraisal of selected publications.</div></div><div><h3>Results</h3><div>The prevalence of FSGS varies significantly between regions. East Asian countries have a relatively low prevalence, with a mean around 7%. In contrast, countries in South Asia, the Middle East and the Americas have a higher prevalence of around 18%. European countries show an intermediate prevalence of about 11%. African countries do not show a clear pattern, with high and low prevalence rates in different countries.</div></div><div><h3>Conclusions</h3><div>The prevalence of FSGS differs by geographic region and ethnicity. While South Asian countries have maintained a consistently low prevalence, other regions have experienced an increase in FSGS cases over time. This study improves the understanding of global patterns of FSGS, providing valuable epidemiological insights for clinicians and researchers.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"45 10","pages":"Article 501404"},"PeriodicalIF":2.6,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145610412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-12DOI: 10.1016/j.nefro.2025.501394
M. Moreiras-Plaza, A. Fijó-Prieto, A. Canto-Calviño, B. Santaclara-Pousada, V. Toledo-Cepeda
Non-infectious complications are common in Peritoneal Dialysis, and usually require imaging tests for diagnosis and evaluation. Computerized tomography (CT)-peritoneography is a CT modality in which, before imaging, radiological contrast is instilled into the peritoneum mixed with the dialysis solution. CT-peritoneography is a simple, fast and accessible test, with a higher diagnostic yield than other more modern imaging techniques, especially in the case of leaks and hernias. We present our experience and results with CT-peritoneography over 10 years. We conclude that CT-peritoneography is the technique of choice for the diagnosis of many of the non-infectious complications in Peritoneal Dialysis, especially in cases of dialysate leakage or hernias.
{"title":"TC-peritoneografía: técnica diagnóstica clave en diálisis peritoneal. Nuestra experiencia","authors":"M. Moreiras-Plaza, A. Fijó-Prieto, A. Canto-Calviño, B. Santaclara-Pousada, V. Toledo-Cepeda","doi":"10.1016/j.nefro.2025.501394","DOIUrl":"10.1016/j.nefro.2025.501394","url":null,"abstract":"<div><div>Non-infectious complications are common in Peritoneal Dialysis, and usually require imaging tests for diagnosis and evaluation. Computerized tomography (CT)-peritoneography is a CT modality in which, before imaging, radiological contrast is instilled into the peritoneum mixed with the dialysis solution. CT-peritoneography is a simple, fast and accessible test, with a higher diagnostic yield than other more modern imaging techniques, especially in the case of leaks and hernias. We present our experience and results with CT-peritoneography over 10 years. We conclude that CT-peritoneography is the technique of choice for the diagnosis of many of the non-infectious complications in Peritoneal Dialysis, especially in cases of dialysate leakage or hernias.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"45 10","pages":"Article 501394"},"PeriodicalIF":2.6,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145610411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-11DOI: 10.1016/j.nefro.2025.501399
Luis M. Ruilope , Bertram Pitt , Alejandro de la Sierra , Gema Ruiz-Hurtado
{"title":"Towards a better prevention in cardio-kidney metabolic syndrome: Role of aldosterone and albuminuria","authors":"Luis M. Ruilope , Bertram Pitt , Alejandro de la Sierra , Gema Ruiz-Hurtado","doi":"10.1016/j.nefro.2025.501399","DOIUrl":"10.1016/j.nefro.2025.501399","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"45 9","pages":"Article 501399"},"PeriodicalIF":2.6,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145384312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-22DOI: 10.1016/j.nefro.2025.501390
E. García-Menéndez, J. Portolés, A. Muñoz-Sánchez, A. Tato Ribera, C. Yuste Lozano, M. Ossorio González, P. López-Sánchez, D. Janeiro Marín
{"title":"Respuesta a la carta al editor «Sarcopenia: la importancia de las fórmulas»","authors":"E. García-Menéndez, J. Portolés, A. Muñoz-Sánchez, A. Tato Ribera, C. Yuste Lozano, M. Ossorio González, P. López-Sánchez, D. Janeiro Marín","doi":"10.1016/j.nefro.2025.501390","DOIUrl":"10.1016/j.nefro.2025.501390","url":null,"abstract":"","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"45 9","pages":"Article 501390"},"PeriodicalIF":2.6,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145384319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号